12 Results for "

glycolytic flux

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "glycolytic flux" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-128788A
ddhCTP trisodium solution (100 mM ± 3 mM) is an endogenously produced pyrimidine base analog with a Kd of 17.0 nM for LLDH and an IC50 of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP trisodium reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP trisodium terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP trisodium can be used in studies related to viral infections, COVID-19 and Zika virus infections .
loading...
    loading...
Cat. No.: HY-113167
CAS No.: 2553-59-5
Synonyms: DL-2-phosphoglyceric acid
2-Phosphoglyceric acid (DL-2-phosphoglyceric acid) is a glycolytic substrate that is catalyzed by enolase to form phosphoenolpyruvate ester (PEP). 2-Phosphoglyceric acid inhibits the ferroptosis pathway by down-regulating ACSL4 and up-regulating GPX4, and has significant neuroprotective effects. 2-Phosphoglyceric acid reflects the overall metabolic state and flux of the cell .
loading...
    loading...
Cat. No.: HY-117778
CAS No.: 107729-45-3
Purity:  ≥95.0%
SF2312 is a phosphonate Antibiotic and Enolase inhibitor, with an IC50 of 18.4 nM against E. coli enolase. SF2312 reduces intracellular ATP levels and inhibits glycolytic flux. SF2312 exhibits activity against both Gram-positive and Gram-negative bacteria, and exerts synergistic effects against E. coli when combined with Fosfomycin (HY-B1075A). SF2312 shows selective toxicity toward gliomas with ENO1 gene knockout. SF2312 can be used in research related to bacterial infections and gliomas .
loading...
    loading...
Cat. No.: HY-128788
CAS No.: 2279171-34-3
ddhCTP is an endogenously produced pyrimidine base analog with a Kd of 17.0 nM for LLDH and an IC50 of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP can be used in studies related to viral infections, COVID-19 and Zika virus infections.
loading...
    loading...
Cat. No.: HY-117778B
Purity:  ≥98.0%
Research Areas:  

Infection Cancer

SF2312 ammonium is a phosphonate Antibiotic and Enolase inhibitor, with an IC50 of 18.4 nM against E. coli enolase. SF2312 ammonium reduces intracellular ATP levels and inhibits glycolytic flux. SF2312 ammonium exhibits activity against both Gram-positive and Gram-negative bacteria, and exerts synergistic effects against E. coli when combined with Fosfomycin (HY-B1075A). SF2312 ammonium shows selective toxicity toward gliomas with ENO1 gene knockout. SF2312 ammonium can be used in research related to bacterial infections and gliomas .
loading...
    loading...
Cat. No.: HY-P2819
CAS No.: 9001-80-3
Synonyms: PFK1
Phosphofructokinase 1 (PFK1) is a glycolytic enzyme and also an allosteric activation target of fructose-2,6-bisphosphate. PFK1 supports cardiac glycolysis to maintain normal cardiac function and mediates adaptive responses to pressure overload. Upregulated expression and activity of PFK1 are associated with the alleviation of pathological changes induced by pressure overload, including diastolic dysfunction, interstitial fibrosis and myocardial hypertrophy. Inhibition of PFK1 redirects glucose carbon flux to the pentose phosphate pathway. PFK1 promotes proliferation, migration and glycolysis of colorectal cancer cells, reduces apoptosis and decreases their radiosensitivity, and shows higher expression levels in radioresistant tumors. PFK1 can be used in research related to diastolic dysfunction heart failure and colorectal cancer .
loading...
    loading...
Cat. No.: HY-182811
CAS No.: 1241957-37-8
AT-051/43421517 is a PGK1 activator with a Kd of 2.45 μM. AT-051/43421517 induces enhanced glycolytic metabolism and maintains TCA cycle activity, while inhibiting ROS production and Apoptosis. AT-051/43421517 reduces deposition and Tau hyperphosphorylation. AT-051/43421517 alleviates neuropathological damage in the brains of 3×Tg-AD mice. AT-051/43421517 improves cognitive impairment. AT-051/43421517 can be used for research on Alzheimer's disease and Parkinson's disease .
loading...
    loading...
Cat. No.: HY-189236
CAS No.: 3111620-80-2
Research Areas:  

Cancer

XJ-4-85 is a covalent activator and precursor compound targeting PFKL (EC50=56 μM in human PFKL). XJ-4-85 activates glycolysis, increases FBP production and glycolytic flux, and enhances LPS-stimulated proinflammatory cytokine release in macrophages. XJ-4-85 causes long-chain acylcarnitine accumulation, metabolic stress, and cytotoxicity through the release of the active payload XJ-4-119 targeting CPT2. XJ-4-85 exhibits broad and selective cytotoxicity across multiple cancer cell lines and is useful for melanoma research .
loading...
    loading...
Cat. No.: HY-184148
Target:  

Phosphatase

Research Areas:  

Cancer

PFKFB3-IN-3 is a selective PFKFB3 inhibitor with a Ki value of 0.09 μM. PFKFB3-IN-3 reduces cancer cell viability, inhibits tumor growth in xenograft models, and acts as a chemosensitizer to exert synergistic effects with chemotherapeutic agents. The limited cellular activity of PFKFB3-IN-3 restricts its application as a chemical probe, but it demonstrates that the Cys154 residue of PFKFB3 is druggable. PFKFB3-IN-3 can be used for the research of pancreatic ductal adenocarcinoma .
loading...
    loading...
Cat. No.: HY-P2819A
CAS No.: 9001-80-3
Phosphofructokinase,Bacillus stearothermophilus is a glycolytic enzyme and also an allosteric activation target of fructose-2,6-bisphosphate. PFK1 supports cardiac glycolysis to maintain normal cardiac function and mediates adaptive responses to pressure overload. Upregulated expression and activity of PFK1 are associated with the alleviation of pathological changes induced by pressure overload, including diastolic dysfunction, interstitial fibrosis and myocardial hypertrophy. Inhibition of PFK1 redirects glucose carbon flux to the pentose phosphate pathway. PFK1 promotes proliferation, migration and glycolysis of colorectal cancer cells, reduces apoptosis and decreases their radiosensitivity, and shows higher expression levels in radioresistant tumors. PFK1 can be used in research related to diastolic dysfunction heart failure and colorectal cancer .
loading...
    loading...
Cat. No.: HY-181267
ALDOA-IN-1 is an aldolase A(ALDOA) inhibitor. ALDOA-IN-1 directly inhibits ALDOA enzymatic activity, thereby reducing lactate production, downregulating HIF-1α expression, and ultimately inducing cancer cell apoptosis. ALDOA-IN-1 can be used for research on colorectal cancer .
loading...
    loading...
Cat. No.: HY-179631
Target:  

Apoptosis

Research Areas:  

Cancer

2DG-ODDA is a 2-deoxyglucose (2-DG) (HY-13966) derivative with potent antitumor activity. 2DG-ODDA induces apoptosis, and reduces ATP production. 2DG-ODDA is taken up through both fatty acid and glucose transporters and is cleaved by α-Mannosidase (HY-P2950), releases 2DG to inhibit N-glycosylation and disrupt cellular metabolism. 2DG-ODDA inhibits tumor growth in a 4T1 mouse model. 2DG-ODDA can be used for the research of triple-negative breast cancer (TNBC) .
loading...
    loading...
  • 1